A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer

StatusActive, Not Recruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 4 more changesShow less
    • Final enrollment: 30 participants (planned 40)
    • Eligibility criteria expanded, about 38 words
    • Secondary endpoints: details revised at 1 of 8 entries
    • Site details revised at 9 of 9 sites
  2. Study sites: 5 to 9
    • Eligibility criteria shortened, about 22 words
    v5
  3. Study sites: 4 to 5v4
  4. Start date changed from estimate of Apr 27, 2025 to Apr 30, 2025v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Oct 9, 2024 to Apr 27, 2025
    • Study sites: 1 to 4
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).
Trial Details
NCT Number NCT06623136
Lead Sponsor Elpiscience (Suzhou) Biopharma, Ltd.
Conditions
(from sponsor)		 Non-Small Cell Lung Cancer
Related terms Carcinoma, Non-Small-Cell Lung
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov